Abdelrahman Aboushouk, M.D.
KCEA-APO(a)-LRx Trial: Anti-sense Oligonucleotide Shows Promise in Reducing Blood Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease
A study led by Dr. Sotirios Tsimikas published in the New England Journal of Medicine showed that the hepatocyte-directed antisense oligonucleotide APO(a)-LRx significantly reduced the blood lipoprotein(a) [Lp(a)] levels in patients with established cardiovascular disease in a dose-dependent manner.
